Validation of the model in a panel of 65 lung cancer cell lines perturbed using PI3K and EGFR/ERBB2 signaling pathway inhibitors revealed general rules of the signaling pathway topology downstream of genetically altered EGFR and ERBB2 kinases. Here, EGFR is linked to lung carcinoma.